利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.042 秒)

    Oncogene- or virus-controlled expression systems
    13.
    发明授权
    Oncogene- or virus-controlled expression systems 失效
    致癌基因或病毒控制的表达系统

    公开(公告)号：US06465246B1

    公开(公告)日：2002-10-15

    申请号：US09196099

    申请日：1998-11-20

    申请人： Rolf Mueller ,  Hans-Harald Sedlacek

    发明人： Rolf Mueller ,  Hans-Harald Sedlacek

    IPC分类号： C12N1509

    CPC分类号： C07K14/4702 ,  A61K38/00 ,  A61K48/00 ,  C12N15/635 ,  C12N15/85 ,  C12N2830/007 ,  C12N2840/20

    摘要： Nucleic acid constructs for expressing an effector gene, with the nucleic acid construct comprising a promoter I (component a) which controls the expression of a transcription factor gene (component b), a transcription factor gene (component b), a promoter II (component c) to which the gene product of the transcription factor gene binds and which controls the expression of an effector gene (component d), and effector gene (component d), wherein the activity of the gene product of the transcription factor gene depends on one or more cellular regulatory proteins which bind to this gene product and affect its activity, and isolated cells containing the nucleic acid constructs, can be used for preparing a drug for treating diseases and in methods of treating diseases.

    摘要翻译： 用于表达效应基因的核酸构建体，其核酸构建体包含控制转录因子基因（组分b）表达的启动子I（组分a），转录因子基因（组分b），启动子II（组分 c）转录因子基因的基因产物结合并控制效应基因（组分d）和效应基因（组分d）的表达，其中转录因子基因的基因产物的活性取决于一个 或更多结合该基因产物并影响其活性的细胞调节蛋白和含有核酸构建体的分离的细胞可用于制备用于治疗疾病的药物和治疗疾病的方法。

    Self-enhancing, pharmacologically controllable expression systems
    14.
    发明授权
    Self-enhancing, pharmacologically controllable expression systems 失效

    公开(公告)号：US06383785B1

    公开(公告)日：2002-05-07

    申请号：US08987348

    申请日：1997-12-09

    申请人： Rolf Mueller ,  Hans-Harald Sedlacek

    发明人： Rolf Mueller ,  Hans-Harald Sedlacek

    IPC分类号： C12N1566

    CPC分类号： A61K48/00 ,  A61K38/47 ,  C12N15/63 ,  C12N15/635

    摘要： The invention relates to a nucleic acid construct which constitutes a self-enhancing expression system and which comprises the following components: at least one first structural gene that encodes an active compound; at least one second structural gene that encodes a transcription factor protein; and at least one activation sequence comprised of at least one sequence that binds the transcription factor protein and at least one promoter sequence; wherein each activation sequence activates the expression of a structural gene and the expression of the transcription factor protein; and to the use of the nucleic acid construct for preparing a drug for treating diseases.

    DNA for expression under control of a cell cycle-dependent promoter
    15.
    发明授权
    DNA for expression under control of a cell cycle-dependent promoter 失效
    用于在细胞周期依赖性启动子控制下表达的DNA

    公开(公告)号：US06358732B1

    公开(公告)日：2002-03-19

    申请号：US08793110

    申请日：1997-04-25

    申请人： Hans-Harald Sedlacek ,  Rolf Müller

    发明人： Hans-Harald Sedlacek ,  Rolf Müller

    IPC分类号： C12N1585

    CPC分类号： A61K48/00 ,  A61K38/00 ,  C12N15/85 ,  C12N2830/15 ,  C12N2830/30 ,  C12N2830/85

    摘要： A DNA sequence is disclosed for the genetic therapy of diseases of the central nervous system. The essential components for the DNA sequence are the activator sequence, the promoter module, and the active substance coding gene. The activator sequence is specifically activated in activated endothelial or glial cells. Activation is cell cycle-regulated by the promoter module. The active substance represents an inhibitor of the nerve growth factor, a dopanine metabolism enzyme, and/or a nerve cell protection factor. The disclosed DNA sequence is inserted into a viral or non-viral vector, supplemented with a ligand with affinity for the target cells.

    摘要翻译： 公开了用于中枢神经系统疾病的遗传疗法的DNA序列。 DNA序列的基本组分是激活子序列，启动子模块和活性物质编码基因。 激活剂序列在激活的内皮细胞或神经胶质细胞中被特异性激活。 激活是由启动子模块细胞周期调控的。 活性物质代表神经生长因子的抑制剂，多巴胺代谢酶和/或神经细胞保护因子。 将所公开的DNA序列插入补充有对靶细胞具有亲和力的配体的病毒或非病毒载体中。